Want to see MPLT full AI Analyst Report?
Top Page
MapLight Therapeutics, Inc.
(NASDAQ:MPLT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$8.00
▼(-41.90% Downside)
Action:Reiterated
Date:10/15/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn) and bearish technicals (price far below key moving averages with negative MACD). These are partially offset by a strong balance sheet and positive corporate developments, including encouraging Phase 2 schizophrenia data and added financing runway through 2028.
Positive Factors
Strong balance sheet
Very low leverage and substantial equity provide financial flexibility for an early-stage biotechnology company. This capitalization can support clinical development and reduce immediate dependence on debt financing, although continued losses could erode that cushion over time.
Negative Factors
No revenue and widening losses
A pre-revenue model leaves the company dependent on successful clinical development and future external funding rather than operating income. The sharp increase in annual losses indicates limited operating leverage and a profitability path that remains several milestones away.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Very low leverage and substantial equity provide financial flexibility for an early-stage biotechnology company. This capitalization can support clinical development and reduce immediate dependence on debt financing, although continued losses could erode that cushion over time.
Read all positive factors
MapLight Therapeutics, Inc. (MPLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$454.05M
Dividend YieldN/A
Average Volume (3M)449.02K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees133
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,575,718
10 Day Avg. Volume388,776
30 Day Avg. Volume449,018
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap2.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.27K
Enterprise Value/Ebitda-5.70
Forecast
1Y Price Target
$26.50Price Target Upside92.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MapLight Therapeutics, Inc. Business Overview & Revenue Model
Company Description
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic ...
MapLight Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -585.00K | -578.00K | -701.00K | -556.00K | -574.00K |
| EBITDA | -232.60M | -160.57M | -76.88M | -55.15M | -29.44M |
| Net Income | -229.83M | -161.15M | -77.58M | -55.71M | -30.02M |
Balance Sheet | |||||
| Total Assets | 368.35M | 479.51M | 136.92M | 91.41M | 39.39M |
| Cash, Cash Equivalents and Short-Term Investments | 304.73M | 305.10M | 108.80M | 79.77M | 27.66M |
| Total Debt | 1.99M | 5.80M | 6.58M | 5.92M | 6.27M |
| Total Liabilities | 20.05M | 21.14M | 21.72M | 20.13M | 18.52M |
| Stockholders Equity | 348.30M | 458.37M | 115.19M | 71.28M | 20.87M |
Cash Flow | |||||
| Free Cash Flow | -175.12M | -138.61M | -79.58M | -52.47M | -27.32M |
| Operating Cash Flow | -174.67M | -138.14M | -78.81M | -52.01M | -26.58M |
| Investing Cash Flow | -250.43M | -323.21M | -80.79M | -462.00K | -746.00K |
| Financing Cash Flow | 463.26M | 469.82M | 118.06M | 104.57M | 33.17M |
MapLight Therapeutics, Inc. Technical Analysis
Negative
13.77
Price Trends
10.69
Negative
18.73
Negative
20.68
Negative
Market Momentum
-0.94
Negative
36.31
Neutral
41.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MPLT, the sentiment is Negative. The current price of 13.77 is above the 20-day moving average (MA) of 8.62, above the 50-day MA of 10.69, and below the 200-day MA of 20.68, indicating a bearish trend. The MACD of -0.94 indicates Negative momentum. The RSI at 36.31 is Neutral, neither overbought nor oversold. The STOCH value of 41.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MPLT.
MapLight Therapeutics, Inc. Risk Analysis
MapLight Therapeutics, Inc. disclosed 75 risk factors in its most recent earnings report. MapLight Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MapLight Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $3.45M | -0.04 | -134.03% | ― | ― | 93.96% | |
51 Neutral | $454.05M | -1.58 | -63.84% | ― | ― | ― | |
44 Neutral | $3.74M | -0.17 | -166.67% | ― | ― | 88.77% | |
43 Neutral | $6.79M | -0.09 | -205.45% | ― | ― | 78.16% | |
43 Neutral | $302.68K | ― | -26.63% | ― | 30.12% | -165.46% |
* General Sector Average
MPLT
MapLight Therapeutics, Inc.
8.17
-8.58
-51.22%
SCNI
Scinai Immunotherapeutics
0.53
-14.47
-96.46%
GRI
GRI Bio
1.58
-52.74
-97.09%
DRMA
Dermata Therapeutics
0.76
-3.01
-79.92%
AZTR
Azitra Inc
1.12
-3.82
-77.31%
MapLight Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
MapLight Bolsters Schizophrenia Program With New Financing Round
Positive
Aug 13, 2026
On August 13, 2026, MapLight Therapeutics reported second-quarter 2026 results and business updates, highlighting its focus on central nervous system drug candidates ML-007C-MA and ML-004 while concentrating resources on late-stage clinical progra...
Business Operations and Strategy
MapLight Reports Positive Phase 2 Schizophrenia Trial Results
Positive
Jul 27, 2026
On July 27, 2026, MapLight Therapeutics reported topline Phase 2 data from the ZEPHYR trial of ML-007C-MA in adult inpatients with schizophrenia during acute psychotic exacerbations. The study met its primary endpoint, showing statistically signif...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.